Posted by Michael Wonder on 24 Sep 2021
Pear Therapeutics announces additional coverage decisions and formulary adoption of its prescription digital therapeutics
23 September 2021 - More than 30 organizations now provide access to Pear’s prescription digital therapeutics by either listing on formulary, as a covered benefit, or purchasing products in bulk.
Pear Therapeutics today updated the number of entities providing coverage for its three commercial products, reSET, reSET-O and Somryst.
